Vol.53 No.11 November 2005
Pazufloxacin mesilate therapy of Legionella pneumonia case report
Department of Respiratory Medicine, South Miyagi Medical Center,
38-1 Aza Nishi, Ohgawara, Shibata-gun, Miyagi, Japan
Abstract
Clinicians need to select an appropriate antibacterial agent as soon as possible to stop the rapid progression of Legionella pneumonia. We report the case of a Legionella pneumonia patient who respond well to treatment with pazufloxacin (PZFX) mesilate, a new quinolone antibacterial agent. We treated the patient with PZFX mesilate by intravenous injection twice a day (500 mg/dose) for seven days. Sputum specimens were cultured, and Legionella pneumophila group 1 was detected later. The MIC of PZFX was maintained at 0.015 μg/mL, which is enough to treat Legionella infection. Because Legionella pneumonia can occasionally becomes exacerbated, the most effective antibacterial injection should be selected as the drug of first choice. The only antibacterial injections approved in Japan for the treatment of Legionella infection are PZFX and minocycline. We conclude that PZFX, which is effective against Legionella species and has been designed to be transferred to the sputum and lung tissues, is useful and effective in treating Legionella pneumonia.
Key word
pazufloxacin, Legionella pneumophila, MIC, quinolone, pneumonia
Received
June 14, 2005
Accepted
September 29, 2005
Jpn. J. Chemother. 53 (11): 696-700, 2005
